ClinicalTrials.gg

Program

opugotamig olatansine

In AbbVie’s pipeline, FR-alpha. Its studies are mostly in Fallopian Tube Neoplasms · Endometrial Neoplasms, led by AbbVie.

Furthest: phase 2, since Jun 9, 20252 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie22 open or runningphase 2since Jun 9, 2025Aug 23, 2022Feb 2027phase 1 · NCT05527184
  • Named in AbbVie’s own pipeline as IMGN-151, phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2022First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT05527184 · 256 enrolled · United States, Australia, Belgium and more
  2. Jun 9, 2025Phase 2 study in Fallopian Tube NeoplasmsNCT07024784 · 377 planned · United States, Israel, Japan

Ahead

  1. Feb 2027Primary completion: phase 1 study in Endometrial NeoplasmsNCT05527184
  2. Jan 2028Primary completion: phase 2 study in Fallopian Tube NeoplasmsNCT07024784

TargetBeta

“FR-alpha”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of opugotamig, an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of folate receptor alpha (FRa; FolRa; FOLR1) that is ”NCIt, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
mirvetuximab soravtansineruleAbbViephase 315
rinatabart sesutecanruleGenmabphase 39
torvutatug samrotecanAstraZenecaphase 35
sofetabart mipitecanEli Lillyphase 32
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07024784Fallopian Tube Neoplasms · United States, Israel, Japan2RecruitingJan 2028377
NCT05527184Endometrial Neoplasms · United States, Australia, Belgium and more1Active, not recruitingFeb 2027256

How it is read

Names in the registry

  • “IMGN151”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.